FDA recognises KER-0193 as a potential therapy for rare paediatric disease
News
Rein Therapeutics initiates renew phase 2 trial for IPF treatment
Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi
Apiary invests in life sciences marketing specialist performance-io
Private equity firm Apiary Capital backs rapid growth of performance-i
Amgen’s Tepezza granted marketing authorisation in the UK
Teprotumumab approved as first targeted treatment for thyroid eye disease
iOnctura starts randomised phase 1/2 trial in lung cancer treatment
Study explores whether PI3Kδ targeting could combat resistance
MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d
UCB’s developmental treatment may be eligible for patient access
PharmaTimes Clinical Researcher of the Year – The Americas Awards
Demonstrate your skill and prowess by entering this year’s awards!
Chiesi partners with Wirral Primary Care to improve COPD detection
New initiative aims to accelerate diagnosis and ease NHS pressures
Johnson & Johnson submits application for subcutaneous Rybrevant dosing
Company seeks approval for new schedules to improve patient convenience
Leqembi dosing proposal for Alzheimer’s treatment validated by MHRA
Application seeks reduced infusion frequency to support patient flexibility
Nice recommends first AI medical device for skin cancer diagnosis in the NHS
Approval marks milestone for AI use in frontline care
Lynozyfic receives EU approval for relapsed multiple myeloma treatment
New therapy offers hope for patients with limited option
Hundreds of genetic links to osteoarthritis unlocked
Study paves the way for personalised therapies for osteoarthritis sufferer
Takeda’s Adcetris receives positive opinion for Hodgkin lymphoma treatment
CHMP recommendation brings new hope for patients
Argenx receives positive CHMP opinion for CIDP treatment
VYVGART could be the first CIDP drug with a novel mechanism in 30 years
